Physician profile
Junaid Pasha
NPI 1659513711
$901.88
in general payments reported to CMS, 2019-2025
23 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.95 · 2020: $14.70 · 2022: $83.60 · 2023: $153 · 2024: $204 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.63 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $171.80 | 2023-2025 | |
| Icotec Medical INC. | $145.32 | 2025 | Kong-Tl Vbr E, Expandable Body, L, 19 Mm X 27 - 37 Mm, Kong-Tl Vbr, End Plate, Rectangular, M and Screw, 12 X 33 Mm, Vader Pedicle System, Rod, Carbon/Peek, Curved, 6.0 R450 X 200 Mm |
| Genzyme Corporation | $53.52 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $49.19 | 2023-2025 | Keytruda, Keytruda Qlex, Reblozyl |
| Eisai INC. | $44.68 | 2023-2024 | |
| Pfizer INC. | $42.91 | 2023-2024 | |
| Genentech USA, INC. | $38.77 | 2022-2025 | Polivy |
| Tactile Systems Technology INC | $29.20 | 2019 | |
| Adaptive Biotechnologies Corporation | $27.21 | 2025 | Clonoseq |
| Daiichi Sankyo INC. | $26.73 | 2022 | |
| Corcept Therapeutics | $26.70 | 2025 | Korlym |
| Novocure INC. | $25.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $25.12 | 2024 | Calquence |
| Janssen Biotech, INC. | $23.60 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.93 | 2025 | Fruzaqla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $22.89 | 2023 | Monoferric |
| Alexion Pharmaceuticals, INC. | $21.56 | 2024 | Ultomiris |
| Acrotech Biopharma INC. | $19.05 | 2023 | Beleodaq |
| Puma Biotechnology, INC. | $18.54 | 2024 | |
| Beone Medicines USA, INC. | $18.07 | 2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $17.87 | 2025 | |
| Sirtex Medical INC | $15.53 | 2019 | |
| Glaxosmithkline, LLC. | $14.77 | 2025 | Ojjaara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junaid Pasha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.